Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Author’ response
Author’s reply
Authors' response
Authors#x2019; response
Book Received
Book Review
Book Reviews
Centenary Review Article
Clinical Image
Clinical Images
Commentary
Communicable Diseases - Original Articles
Correspondence
Correspondence, Letter to Editor
Correspondences
Correspondences & Authors’ Responses
Corrigendum
Critique
Current Issue
Editorial
Errata
Erratum
Health Technology Innovation
IAA CONSENSUS DOCUMENT
Innovations
Letter to Editor
Malnutrition & Other Health Issues - Original Articles
Media & News
Notice of Retraction
Obituary
Original Article
Original Articles
Perspective
Perspectives
Policy
Policy Document
Policy Guidelines
Policy, Review Article
Policy: Correspondence
Policy: Editorial
Policy: Mapping Review
Policy: Original Article
Policy: Perspective
Policy: Process Paper
Policy: Scoping Review
Policy: Special Report
Policy: Systematic Review
Policy: Viewpoint
Practice
Practice: Authors’ response
Practice: Book Review
Practice: Clinical Image
Practice: Commentary
Practice: Correspondence
Practice: Letter to Editor
Practice: Obituary
Practice: Original Article
Practice: Pages From History of Medicine
Practice: Perspective
Practice: Review Article
Practice: Short Note
Practice: Short Paper
Practice: Special Report
Practice: Student IJMR
Practice: Systematic Review
Pratice, Original Article
Pratice, Review Article
Pratice, Short Paper
Programme
Programme, Correspondence, Letter to Editor
Programme: Commentary
Programme: Correspondence
Programme: Editorial
Programme: Original Article
Programme: Originial Article
Programme: Perspective
Programme: Rapid Review
Programme: Review Article
Programme: Short Paper
Programme: Special Report
Programme: Status Paper
Programme: Systematic Review
Programme: Viewpoint
Protocol
Research Correspondence
Retraction
Review Article
Short Paper
Special Opinion Paper
Special Report
Special Section Nutrition & Food Security
Status Paper
Status Report
Strategy
Student IJMR
Systematic Article
Systematic Review
Systematic Review & Meta-Analysis
Viewpoint
White Paper
View/Download PDF

Translate this page into:

Commentary
148 (
2
); 127-129
doi:
10.4103/ijmr.IJMR_969_18

Mediators of insulin resistance & cardiometabolic risk: Newer insights

Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Noncommunicable Diseases Prevention & Control, IDF Centre of Excellence in Diabetes Care & ICMR Centre for Advanced Research on Diabetes, Chennai 600 086, Tamil Nadu, India

*For correspondence: drmohans@diabetes.ind.in

Read COMMENTARY-ARTICLE associated with this -

Licence

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.

Cardiometabolic risk refers to an increased susceptibility to cardiovascular diseases (CVDs) (stroke, myocardial infarction and peripheral artery disease) and metabolic disorders such as type 2 diabetes. Cardiometabolic risk factors include insulin resistance (IR), obesity, elevation in blood glucose, blood pressure, triglycerides and low-density lipoprotein cholesterol (LDL-C), low high-density lipoprotein cholesterol (HDL-C), smoking and inflammatory markers. While IR and obesity have been independently associated with cardiometabolic risk, IR has also been reported to be a critical mediator in the association between obesity and its comorbidities such as type 2 diabetes, hypertension and CVDs. IR has also been used in CV risk prediction models1.

The development and progression of CVD can be assessed by measuring the baroreceptor sensitivity (BRS) index. Studies have shown a reduction in BRS in individuals with metabolic syndrome and IR23, but the degree of BRS in IR and non-IR pre-obese and obese individuals has not been estimated so far. In this context, the study by Indumathy et al4 in this issue gains significance. Moreover, this study has evaluated the link of IR with BRS and cardiometabolic risk in normoglycaemic, normotensive pre-obese and obese adult Indian population. Indians are known to have the ‘Asian phenotype’ or ‘South Asian phenotype’ characterized by greater IR, higher abdominal fat, lower beta cell reserve and increased susceptibility to type 2 diabetes and CVD in spite of lower body mass index. A recent study tested the uniqueness of South Asian phenotype by comparing the cardiometabolic profile in resident South Asians with four different ethnic groups in the United States (US) and found that 8-15 per cent of men and 1-2 per cent of women of diverse ethnic backgrounds in US exhibited cardiometabolic profile similar to the South Asian phenotype5. This shows that the high-risk cardiometabolic profile is seen in other ethnic groups also, albeit at a lower prevalence.

In the study by Indumathy et al4, there was a significant reduction in BRS in the IR group as compared to non-IR group both in the pre-obese and obese categories. When the BRS index was compared between IR pre-obese and IR obese groups, there was no significant difference. This suggests that IR predisposes to CV risk, irrespective of the adiposity status. In fact, IR seems to set in at an earlier age in Asian Indians, and indeed the presence of hyperinsulinaemia has been demonstrated even in the cord blood678.

There are several evidences to suggest that the CV risk associated with IR could be contributed by dyslipidaemia. In the Framingham Heart Study, incident coronary heart disease risk associated with low HDL-C and high triglycerides was significantly increased only in the presence of IR in subjects without type 2 diabetes9. Similar findings have been reported in the normoglycaemic IR individuals studied by Indumathy et al4. They reported a significantly higher cholesterol, triglycerides and LDL-C and lower HDL-C levels in IR as compared to non-IR individuals both in the pre-obese and obese groups.

Inflammation is also an integral part of obesity and IR. Many inflammatory cytokines and adipokines such as tumour necrosis factor-α (TNF-α), interleukin (IL)-1, IL-6, IL-8, IL-10, plasminogen activator inhibitor 1, monocyte chemoattractant protein-1 (MCP-1), retinol binding protein-4, adiponectin, leptin, resistin, visfatin and chemerin, have been shown to be involved in the regulation of IR. The role of TNF-α, IL-6 and adiponectin in IR and obesity has been investigated by many researchers. In the case of abdominal obesity caused by excess visceral adipose tissue, increased amounts of inflammatory cytokines such as TNF-α, IL-6 and chemokines such as MCP-1 are secreted. TNF-α causes IR by inducing serine phosphorylation of insulin receptor substrate 1 (IRS1) and suppression of insulin signal transduction10. IL-6 induces IR by reducing the expression of glucose transporter type 4 (GLUT4) and IRS1 by activating the JAK-STAT signaling pathway and increasing suppressor of cytokine signaling 3 (SOCS3) expression10. Increases in TNF-α and IL-6 induce the production of C-reactive protein (CRP) by the liver. CRP is the commonly used marker to assess systemic inflammation and is considered an inflammatory marker related to CVD11. In line with the existing knowledge on the role of these inflammatory markers in IR and CVD, TNF-α, IL-6 and CRP levels were higher in IR individuals as compared to non-IR individuals in this study4, demonstrating the role of inflammation in IR and increased CV risk.

Adiponectin is a true adipokine which is exclusively produced by the adipose tissue. Binding of adiponectin to its receptors AdipoR1 and AdipoR2 results in activation of adenosine monophosphate-dependent kinase, PPAR-α (peroxisome proliferator-activated receptor-alpha) and other signalling pathways, eventually leading to insulin sensitization. Lower adiponectin levels have been associated with obesity and IR, both of which are the risk factors for cardiometabolic diseases12. The hypoadiponectinaemia reported in the individuals with IR in this study4 could also contribute to the increased CV risk in these individuals.

Based on all the above observations, the proposed conclusions of this study4 are that:

  • (i)

    Pro-inflammatory state, dyslipidaemia and hypoadiponectinaemia might contribute to cardiometabolic risk in IR individuals.

  • (ii)

    The cardiometabolic risk observed in IR individuals is independent of the adiposity status.

  • (iii)

    IR which occurs earlier than other metabolic abnormalities could be used for identifying individuals at increased risk for cardiometabolic diseases.

Although the study needs replication in larger samples before these findings are confirmed, one intriguing question mentioned by the authors themselves is whether the risk observed in these patients could be individual specific4. To investigate this, genetic studies and studies of gut microbiota might be the next logical steps. The role of genetic factors in increasing coronary heart disease risk has been shown in the studies on first-degree relatives, twin pairs, parents and offspring, and similarity of offspring to their biological compared to adoptive parents with heritable estimates of around 0.4-0.613. One of the earliest genome-wide association studies (GWASs) showed that the SNP rs1333049 near CDKN2A and CDKN2B on chromosome 9 was significantly associated with susceptibility to coronary heart disease14. The same locus was also associated with type 2 diabetes in subsequent studies15. Recently, a multi-trait GWAS has identified 53 loci which include 43 new loci for IR16. A genetic profiling of study subjects might give an idea about the cardiometabolic risk carried by these individuals based on number of risk variants carried by them.

The human gut microbiota has been intensively studied in the past few years, and dysbiosis, a change in the composition and function of gut microbiota, has been found to be associated with the pathogenesis of cardiometabolic disorders17. A change in gut microbiota profile has also been shown to be associated with increased CV risk in a study on patients with highest and lowest lifetime burdens of CVD risk factors18. In patients with symptomatic atherosclerosis, Collinsella has been found to be increased and a lower ratio of Bacteroidetes to Firmicutes has been associated with obesity. Changes in the amount of Bifidobacterium, Lactobacillus and Clostridium as well as a reduced Firmicutes to Bacteroidetes ratio have been reported in type 2 diabetes19. In addition, a reduction in the number of Clostridiales bacteria (Roseburia species and Faecalibacterium prausnitzii), which produce short-chain fatty acid (SCFA) such as butyrate, has also been reported1920. Studies have also shown that gut microbial dysbiosis results in increased gut permeability causing absorption of macromolecules from the intestinal content. This triggers systemic immune alterations, altered signalling pathways affecting lipid and glucose metabolism and low-grade inflammation, eventually leading to IR and type 2 diabetes21.

Studies have also shown the role of gut microbiota-derived molecules in cardiometabolic disorders. SCFAs from gut microbiota affect insulin sensitivity, while administration of SCFAs without changing food intake or exercise increased insulin sensitivity in mice fed on a high-fat diet22. It has also been shown that intestinal microbial metabolism contributes to the generation of uraemic retention molecules such as trimethylamine-N-oxide (TMAO)23, which has been implicated in atherosclerosis, platelet aggregation, diabetes, hypertension and chronic kidney disease. Strategies such as administration of TMAO inhibitors, faecal microbiota transplantation and use of prebiotics and probiotics to restore the balance in the microbiome, are being tried in the prevention/treatment of CVD.

More studies on the ‘Asian Indian phenotype’ are needed as this can help us to understand more completely the pathogenesis of IR, the type 2 diabetes and CVD.

Conflicts of Interest: None.

References

  1. , , , , , . Insulin resistance as a predictor of cardiovascular disease in patients on peritoneal dialysis. Perit Dial Int. 2013;33:411-8.
    [Google Scholar]
  2. , , , , . Baroreceptor sensitivity is impaired in elderly subjects with metabolic syndrome and insulin resistance. J Hypertens. 2006;24:143-50.
    [Google Scholar]
  3. , , , , , , . Is reduced baroreflex gain a component of the metabolic syndrome? Insight from the Linosa Study. J Hypertens. 2006;24:361-70.
    [Google Scholar]
  4. , , , , , , . Contribution of insulin resistance to decreased baroreceptor sensitivity and cardiometabolic risks in pre-obesity and obesity. Indian J Med Res. 2018;148:151-8.
    [Google Scholar]
  5. , , , , , , . Is the “South Asian phenotype” unique to South Asians? Comparing cardiometabolic risk factors in the CARRS and NHANES studies. Glob Heart. 2016;11:89-96.e3.
    [Google Scholar]
  6. , , , . Diabetes in South Asians: Is the phenotype different? Diabetes. 2014;63:53-5.
    [Google Scholar]
  7. , , , , , , . High prevalence of insulin resistance in postpubertal Asian Indian children is associated with adverse truncal body fat patterning, abdominal adiposity and excess body fat. Int J Obes Relat Metab Disord. 2004;28:1217-26.
    [Google Scholar]
  8. , , , , , , . Adiposity and hyperinsulinemia in Indians are present at birth. J Clin Endocrinol Metab. 2002;87:5575-80.
    [Google Scholar]
  9. , , , , , . Insulin resistance and the relation of a dyslipidemia to coronary heart disease. The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2011;31:1208-14.
    [Google Scholar]
  10. , , , . Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemokines. ISRN Inflamm. 2013;2013:139239.
    [Google Scholar]
  11. , , , , , , . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
    [Google Scholar]
  12. , , , , , , . Relationship of adipokines and proinflammatory cytokines among Asian Indians with obesity and youth onset type 2 diabetes. Endocr Pract. 2015;21:1143-51.
    [Google Scholar]
  13. , . Genetic insights into cardiometabolic risk factors. Clin Biochem Rev. 2014;35:15-36.
    [Google Scholar]
  14. , , , , , , . A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-91.
    [Google Scholar]
  15. , , , . Replication of recently described type 2 diabetes gene variants in a South Indian population. Metabolism. 2010;59:1760-6.
    [Google Scholar]
  16. , , , , , , . Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:17-26.
    [Google Scholar]
  17. , , . Gut microbiome and its role in cardiovascular diseases. Curr Opin Cardiol. 2017;32:761-6.
    [Google Scholar]
  18. , , , , , , . Gut microbiome associates with lifetime cardiovascular disease risk profile among Bogalusa Heart Study participants. Circ Res. 2016;119:956-64.
    [Google Scholar]
  19. , , , , , , . A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60.
    [Google Scholar]
  20. , , , , , , . Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99-103.
    [Google Scholar]
  21. , , , , , , . Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20:16079-94.
    [Google Scholar]
  22. , , , , , , . Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64:2398-408.
    [Google Scholar]
  23. , , , , , , . Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: Refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908-14.
    [Google Scholar]

    Fulltext Views
    23

    PDF downloads
    10
    View/Download PDF
    Download Citations
    BibTeX
    RIS
    Show Sections
    Scroll to Top